Novo Nordisk Q4 Preview: Rybelsus’s Launch Key Focus

Analysts Expect Strong Q4 GLP-1 Volumes Offset By US Pricing Pressures

 
• By Sten Stovall
  
Novo Nordisk
Novo Nordisk is becoming increasingly reliant on the high-growth GLP-1 class • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip